1 Global Antibiotics Market Size, Share, Growth, Trends and Forecasts (2035)

Antibiotics Market

Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies), Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2023

  • Slides
    175

  • View Count
    254

Bacterial infections are known to be one of the leading causes of deaths, worldwide. In fact, infections caused by bacteria are responsible for every one out of eight deaths, globally. This can be attributed to the fact that majority of the pathogenic bacteria have developed resistance against the commonly prescribed therapies. In addition, as per the Centers for Disease Control and Prevention (CDC), the annual healthcare cost associated with treatment of infections caused by six multi-drug resistant bacteria is estimated to be more than USD 4.6 billion in the US. Antibiotics (chemical substances derived from the biological sources or produced chemically) are extensively being used for the prevention / treatment of various bacterial infections. Over the past few years, a number of novel broad-spectrum (antibiotics that provide therapeutic effects against a wide range of bacteria) and narrow spectrum (antibiotics that provide therapeutic effects against specific bacterial strains only) antibiotic therapies, targeting a myriad of bacterial infections (in alphabetical order), including anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis, have received approval from various regulatory authorities, globally. However, the antibiotic drug development is currently fraught with several challenges, including emergence of drug-resistant bacteria and concerns related to safety and efficacy of these therapies. 

In order to address the aforementioned concerns, several industry stakeholders have been actively leading the efforts for research and development of effective and safe antibiotics. In addition, over the years, several regulatory organizations, including the World Health Organization (WHO), CDC and United States Food and Drug Administration (USFDA) have undertaken various initiatives to not only promote the correct usage of antibiotics but also support the players engaged in this industry. The continuous efforts of both industry and non-industry players as well as regulatory organizations, combined with the increasing patient population, are expected to be the key drivers for growth in the antibiotics market in the coming years.

Key Market Insights

The Global Antibiotics Market - Distribution by Type of Drug Class (Aminoglycosides, Cephalosporins, Fluoroquinolones, Macrolides, Oxazolidinones, Penicillins, Sulphonamides, Tetracyclines and Other Drug Classes), Target Disease Indication (Bacterial Infections, Dermatological Infections, Gastrointestinal Infections, Hematological Infections, Nephrological Infections, Pulmonary Infections, Reproductive Tract Infections, Respiratory Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infections and Other Bacterial Infections), Type of Therapy (Monotherapies and Combination Therapies), Route of Administration (Intravenous and Oral), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), and Drug-wise Sales: Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players involved in the development of antibiotics. The report answers many key questions related to this domain.

Need for Novel Antibiotics Targeting Multi-drug Resistant Bacterial Infections

Over the years, due to overuse of antibiotics, bacterial strains have developed resistance to most of the commercially available antibiotics, a phenomenon known as antibiotic / antimicrobial resistance (AMR). Notably, in November 2021, the World Health Organization (WHO) declared AMR as one of the top ten threats for the global public health standards. In order to address the aforementioned challenge, drug developers are currently evaluating various novel antibiotics. These novel antibiotics belong to previously unexplored drug classes that can target new pathways to inhibit bacterial growth. In addition, some of these therapies are being evaluated to overcome the challenges of cross resistance (commonly observed in currently available antibiotics).

Current Market Landscape of Antibiotics

Since 1980, close to 50 unique antibiotics have been approved for the prevention / treatment of various infections caused by gram negative as well as gram positive bacteria. Further, in the last eight years, developers have received approvals for more than 25 novel antibiotics intended for the treatment of multiple infectious diseases. It is worth highlighting that over 150 antibiotics are currently being evaluated in more than 1,720 trials across different stages of preclinical / clinical development, either as monotherapies or combination therapies. Majority of these clinical-stage antibiotics are being developed for the treatment of infections caused by members of Enterobacteriaceae family. 

Partnership and Collaboration Trends in Antibiotics Domain

Currently, several partnerships have been inked by various industry and non-industry players engaged in the development of antibiotics. It is worth highlighting that 30% of these partnerships were inked in 2022. Majority of such deals are focused on joint development of antibiotics, followed by agreements signed for the purpose of research and development, product development and commercialization of antibiotics. 

Impact of COVID-19 on the Antibiotics Industry

It is worth highlighting that a significant surge has been observed in the use of antibiotics, since 2020. This can be attributed to the fact that various antibiotic generics, namely azithromycin, ceftriaxone, moxifloxacin and meropenem, were used extensively in the initial phase of the pandemic. However, the COVID-19 pandemic caused the disruption of the supply chain of antibiotics. Hence, in order to address the increasing demand as well as overcome the aforementioned supply chain-related disruption, a number of developers based in North America and Europe either expanded their facilities or established new facilities for the manufacturing of antibiotics.

Key Drivers for the Antibiotics Market

The increasing prevalence of various infections caused by both gram positive and gram-negative bacteria is one of the key drivers for the antibiotics market. In addition, emergence of multi-drug resistant bacteria, current unmet need for novel antibiotics and extensive research and development initiatives by industry players are expected to drive the growth in antibiotics market in the coming years.

Market Size of Antibiotics

Driven by the increasing need for novel antibiotics, along with growing development pipeline and encouraging clinical trial results, the antibiotics market is anticipated to grow at a steady pace in the coming years. Specifically, in terms of target disease indication, the market is anticipated to be driven by therapies being developed for the treatment of urinary tract infections, and dermatological infections. Additionally, it is worth highlighting that majority of the current market share is captured by players based in North America and Asia-Pacific.

Key Players in the Antibiotics Market

Examples of the key players in this domain (the complete list of players is available in the full report) include ABAC Therapeutics, Bayer, Biocidium Biopharmaceuticals, Blacksmith Medicines, Bristol Myers Squibb, Crestone, Daiichi Sankyo, Debiopharm, Fedora Pharmaceuticals, Fujisawa Pharmaceutical, GlaxoSmithKline, Helperby Therapeutics, Madam Therapeutics, Melinta Therapeutics, Meiji Seika Pharma, MicuRx Pharmaceuticals, Merck, Pfizer, Qpex Biopharma, RedHill Biopharma, Selmod, Sequella, Sinovent, Spero Therapeutics and Wockhardt.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:

Key Report Attributes Details

Forecast Period

  • 2023 – 2035

Type of Drug Class

  • Aminoglycosides
  • Cephalosporins
  • Fluoroquinolones
  • Macrolides
  • Oxazolidinones
  • Penicillins
  • Sulphonamides
  • Tetracyclines
  • Other Drug Classes

Target Disease Indication

  • Bacterial Infections
  • Dermatological Infections
  • Gastrointestinal Infections
  • Hematological Infections
  • Nephrological Infections
  • Pulmonary Infections
  • Reproductive Tract Infections
  • Respiratory Tract Infections
  • Sexually Transmitted Diseases
  • Urinary Tract Infections
  • Other Bacterial Infections

Type of Therapy

  • Monotherapies
  • Combination therapies

Route of Administration

  • Intravenous
  • Oral

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Key Companies Profiled

  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Melinta Therapeutics
  • Merck
  • Pfizer
  • (Full list of 190+ companies captured available in the report)

Customization Scope

  • 15% Free Customization Option (equivalent to 5 analyst working days)

Excel Data Packs (Complimentary)

  • Approved Antibiotic Generics Market Landscape
  • Approved Antibiotic Brands Market Landscape
  • Clinical-stage Antibiotics Market Landscape
  • Partnership and Collaboration Analysis
  • Clinical Trials Analysis
  • KOL Analysis
  • Success Protocol Analysis
  • Market Forecast and Opportunity Analysis

 

The study presents detailed information on current market landscape and future opportunities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the global antibiotics market and its likely evolution in the mid-to-long term.
  • A general introduction to antibiotics, along with information on their characteristics and advantages, and classification (based on chemical structure, mode of action, range of activity and source). In addition, the chapter highlights details on the history of antibiotics, innovations related to antibiotics, mechanism of action of antibiotics and challenges associated with their use. Further, it concludes with a discussion on the future perspectives in this domain.
  • A detailed assessment of the overall market landscape of approved antibiotic generics, based on several relevant parameters, such as year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (alteration of cell membranes, cell wall synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and RNA polymerase inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral, topical and others / unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and others), and type of patient population (based on age and gender). In addition, it provides an in-depth analysis on the developers engaged in the development of antibiotic generics, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of approved generics). 
  • A detailed assessment of the overall market landscape of approved antibiotic brands, based on several relevant parameters, such as year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (cell wall synthesis inhibition, DNA synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition and protein synthesis inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative  and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous and oral), dosage form(s) (capsules, creams, liquids, powder, tablets and others), type of patient population (based on age and gender) and type of innovation. In addition, it provides an in-depth analysis on the developers engaged in the development of antibiotic brands, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of approved brands). 
  • A detailed assessment of the overall market landscape of clinical-stage antibiotics, based on several relevant parameters, such as status of development (clinical and preclinical), stage of development, type of antibiotic (based on chemical structure and drug class), mechanism of action (cell membrane alteration, cell wall synthesis inhibition, FABI inhibition, fatty acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and others), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative and gram positive), target bacterial strain(s), target disease indication(s), therapeutic area(s) (genetic disorder, immunological disorder, infectious disease, oncological disorder, renal disorder and sexually transmitted disease), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral and others / unspecified), dosage form(s) (capsules, liquids, tablets and others / unspecified), dosage strength, dosage frequency, dosing period, type of patient population (based on age and gender) and special designation received (breakthrough therapy, fast track, orphan drug and qualified infectious disease product). In addition, it provides an in-depth analysis on the companies engaged in the development of clinical-stage antibiotics, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of clinical-stage antibiotics and number of preclinical-stage antibiotics).
  • Elaborate profiles of key players engaged in the development of antibiotics (shortlisted based on proprietary criterion), including a brief overview of the company, key executives, financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter highlights the key strategies and key focus areas of the developers, along with expert opinion. 
  • A detailed analysis of partnerships inked between stakeholders engaged in this domain, since 2017, based on several relevant parameters, such as year of partnership, type of partnership (acquisitions, commercialization agreements, distribution agreements, joint development agreements, licensing agreements, manufacturing agreements, product development agreements, product development and commercialization agreements, research and development agreements, technology utilization agreements and others), type of partner, company size, most active players (in terms of number of partnerships)., and regional distribution of partnership activity in this domain.
  • An analysis of completed and ongoing clinical studies related to antibiotics, based on several relevant parameters, such as trial registration year, trial status, trial phase, type of patient population (based on gender), key focus areas, type of sponsor, geography and most active industry and non-industry players (in terms of number of trials).
  • An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibiotics, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication(s). In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
  • An elaborate discussion on key trends within the antibiotics industry providing insights on drug-pricing, outsourcing trends and impact of COVID-19 on the antibiotics domain.
  • An insightful success protocol analysis of recently approved antibiotics, based on several relevant parameters, such as dosing frequency, drug efficacy, geographical reach, inter-class competition, intra-class competition, t innovation feature, price, prevalence, route of administration, spectrum of activity, type of therapy and type of target bacteria.

One of the key objectives of this report was to estimate the current opportunity and the future growth potential of the global antibiotics market over the coming years. We have provided an informed estimate on the likely evolution of the market in mid-term to long term for the period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of drug class (aminoglycosides, cephalosporins, fluoroquinolones, macrolides, penicillins, sulfonamides, tetracyclines and other classes), target disease indication (bacterial infections, dermatological infections, gastrointestinal infections, hematological infections,  nephrological infections, pulmonary infections, reproductive tract infections, respiratory tract infections, sexually transmitted diseases, urinary tract infections and  other bacterial infections), type of therapy (monotherapies and combination therapies), route of administration (intravenous and oral) and geography (North America, Europe, Asia-Pacific and Rest of the world). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

 

Frequently Asked Questions

Question 1: What are antibiotics?

Answer: Antibiotics are chemical substances that are either derived from biological sources or produced chemically. These chemicals are used for the prevention / treatment of various bacterial infections.

Question 2: What are the top 10 antibiotics?

Answer: The top 10 antibiotics (in alphabetical order) are amoxicillin, azithromycin, cephalexin, ciprofloxacin, clavulanate, clindamycin, doxycycline, levofloxacin, metronidazole, and sulfamethoxazole.

Question 3: How many novel antibiotics have been approved for the treatment of bacterial infections over the years?

Answer: Since 2016, more than 25 antibiotics have been approved by various regulatory organizations, across the globe.

Question 4: How many companies develop antibiotics?

Answer: 50 industry players are currently engaged in the evaluation and development of over 150 potential antibiotics for the treatment of patients suffering from a wide array of bacterial infections.

Question 5: What are the key types of partnerships and collaborations signed in the antibiotics industry?

Answer: Currently, research and development agreements, joint development agreements and product development and commercialization agreements are the common types of partnerships inked by developers that are currently focused on the development of antibiotics.

Question 6: What is the growth rate of antibiotics market?

Answer: The antibiotics market is expected to grow at a steady rate in the period 2023-2035.

Table Of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION
2.1. Overview of Antibiotics
2.2. Characteristics of an Ideal Antibiotic
2.3. Advantages of Antibiotics
2.4. Classification of Antibiotics
2.5. History of Antibiotics
2.6. Innovations in Antibiotics
2.7. Mechanism of Action of Antibiotics
2.8. Challenges associated with the use of Antibiotics
2.9. Future Perspectives

3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS
3.1. Approved Antibiotic Generics: Overall Market Landscape
3.1.1. Analysis by Year of Approval
3.1.2. Analysis by Region(s) of Approval
3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
3.1.5. Analysis by Mechanism of Action
3.1.6. Analysis by Spectrum of Activity
3.1.7. Analysis by Type of Target Bacteria(s)
3.1.8. Analysis by Target Bacterial Strain(s)
3.1.9. Analysis by Target Disease Indication(s)
3.1.10. Analysis by Nature of Source
3.1.11. Analysis by Type of Therapy
3.1.12. Analysis by Route(s) of Administration
3.1.13. Analysis by Dosage Form(s)
3.1.14. Analysis by Type of Patient Population (based on Age)
3.1.15. Analysis by Type of Patient Population (based on Gender)

3.2. Approved Antibiotic Generics: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Analysis by Location of Headquarters
3.2.4. Most Active Players: Analysis by Number of Approved Generics

4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
4.1. Approved Antibiotic Brands: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Region(s) of Approval
4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
4.1.5. Analysis by Mechanism of Action
4.1.6. Analysis by Spectrum of Activity
4.1.7. Analysis by Type of Target Bacteria
4.1.8. Analysis by Target Bacterial Strain(s)
4.1.9. Analysis by Target Disease Indication(s)
4.1.10. Analysis by Nature of Source
4.1.11. Analysis by Type of Therapy
4.1.12. Analysis by Route(s) of Administration
4.1.13. Analysis by Dosage Form(s)
4.1.14. Analysis by Type of Patient Population (based on Age)
4.1.15. Analysis by Type of Patient Population (based on Gender)
4.1.16. Analysis by Type of Innovation

4.2. Approved Antibiotic Brands: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.4. Analysis by Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Approved Brands

5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
5.1. Clinical-stage Antibiotics: Overall Market Landscape
5.1.1. Analysis by Status of Development
5.1.2. Analysis by Stage of Development
5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
5.1.5. Analysis by Mechanism of Action
5.1.6. Analysis by Spectrum of Activity
5.1.7. Analysis by Type of Target Bacteria(s)
5.1.8. Analysis by Target Bacterial Strain(s)
5.1.9. Analysis by Target Disease Indication(s)
5.1.10. Analysis by Therapeutic Area(s)
5.1.11. Analysis by Nature of Source
5.1.12. Analysis by Type of Therapy
5.1.13. Analysis by Route(s) of Administration
5.1.14. Analysis by Dosage Form(s)
5.1.15. Analysis by Dosage Strength
5.1.16. Analysis by Dosage Frequency
5.1.17. Analysis by Dosing Period
5.1.18. Analysis by Type of Patient Population (based on Age)
5.1.19. Analysis by Type of Patient Population (based on Gender)
5.1.20. Analysis by Special Designation Received

5.2. Clinical-stage Antibiotics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

6. COMPANY PROFILES
6.1. Bristol-Myers Squibb
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments
6.1.6. Key Strategies
6.1.7. Key Focus Areas
6.1.8. Expert Opinion

6.2. Daiichi Sankyo
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments
6.2.6. Key Strategies
6.2.7. Key Focus Areas
6.2.8. Expert Opinion

6.3. GlaxoSmithKline
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments
6.3.6. Key Strategies
6.3.7. Key Focus Areas
6.3.8. Expert Opinion

6.4. Melinta Therapeutics
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Financial Information
6.4.4. Product Portfolio
6.4.5. Recent Developments
6.4.6. Key Strategies
6.4.7. Key Focus Areas
6.4.8. Expert Opinion

6.5. Merck
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments
6.5.6. Key Strategies
6.5.7. Key Focus Areas
6.5.8. Expert Opinion

6.6. Pfizer
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments
6.6.6. Key Strategies
6.6.7. Key Focus Areas
6.6.8. Expert Opinion

6.7. Concluding Remarks

7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS
7.1. Partnership Models
7.2. Antibiotics: List of Partnerships and Collaborations
7.2.1. Analysis by Year of Partnership
7.2.2. Analysis by Type of Partnership
7.2.3. Analysis by Type of Partner
7.2.4. Analysis by Company Size
7.2.5. Local and International Agreements
7.2.6. Intracontinental and Intercontinental Agreements
7.2.7. Most Active Players: Analysis by Number of Partnerships
7.2.8. Concluding Remarks

8. CLINICAL TRIAL ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Antibiotics: Clinical Trial Analysis
8.2.1. Analysis by Trial Registration Year
8.2.2. Analysis by Trial Status
8.2.3. Analysis by Trial Phase
8.2.4. Analysis by Type of Patient Population (based on Gender)
8.2.5 Word Cloud Analysis: Key Focus Areas
8.2.6. Analysis by Type of Sponsor
8.2.7. Analysis by Geography
8.2.8. Most Active Industry Players: Analysis by Number of Trials
8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials

9. KEY OPINION LEADERS
9.1. Assumptions and Key Parameters
9.2. Methodology
9.3. Antibiotics: Key Opinion Leaders (KOLs)
9.3.1. Analysis by Type of KOL
9.3.2. Analysis by Qualification
9.3.3. Analysis by Type of Organization
9.3.4. Analysis by Affiliated Organization
9.3.5. Analysis by Geographical Location of KOLs
9.3.6. Analysis by Target Disease Indication(s)
9.3.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
9.3.8 Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
9.3.9. Most Prominent KOLs: Analysis by RA score
9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.3.11. Concluding Remarks

10. KEY TRENDS IN ANTIBIOTICS INDUSTRY
10.1. Antibiotics Industry: Drug-Pricing Analysis
10.2. Antibiotics Industry: Outsourcing Trends
10.3. Antibiotics Industry: Impact of COVID-19

11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands
11.3.1. Dovprela (TB Alliance)
11.3.1.1. Drug Overview
11.3.1.2. Success Protocol Analysis

11.3.2. Fetroja (Shionogi)
11.3.2.1. Drug Overview
11.3.2.2. Success Protocol Analysis

11.3.4. Kimyrsa (Melinta Therapeutics)
11.3.4.1. Drug Overview
11.3.4.2. Success Protocol Analysis

11.3.5 Recarbrio (Merck)
11.3.5.1. Drug Overview
11.3.5.2. Success Protocol Analysis

11.3.6. Quofenix (Menarini)
11.3.6.1. Drug Overview
11.3.6.2. Success Protocol Analysis

11.3.9 Xenleta (Nabriva Therapeutics)
11.3.9.1. Drug Overview
11.3.9.2. Success Protocol Analysis

11.4. Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Antibiotics Market, 2023-2035
12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035
12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2035
12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2035
12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2035
12.3.1.4. Antibiotics Market for Macrolides, 2023-2035
12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2035
12.3.1.6. Antibiotics Market for Penicillins, 2023-2035
12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2035
12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2035
12.3.1.9. Antibiotics Market for Other Classes, 2023-2035

12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035
12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2035
12.3.2.2. Antibiotics Market for Dermatological Infections, 2023-2035
12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2035
12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2035
12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2035
12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2035
12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2035
12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2035
12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2035
12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2035
12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2035

12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035
12.3.3.1. Antibiotics Market for Monotherapies, 2023-2035
12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2035

12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2035
12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2035
12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2035

12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2035
12.3.5.1. Antibiotics Market in North America, 2023-2035
12.3.5.2. Antibiotics Market in Europe, 2023-2035
12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2035
12.3.5.3. Antibiotics Market in Rest of the World, 2023-2035

12.3.6. Sales Forecast: Approved Antibiotics
12.3.6.1. Aemcolo®: Sales Forecast, 2023-2035
12.3.6.2. Arikayce®: Sales Forecast, 2023-2035
12.3.6.3. Baxdela™: Sales Forecast, 2023-2035
12.3.6.4. Dalacin C: Sales Forecast, 2023-2035
12.3.6.5. Dovprela®: Sales Forecast, 2023-2035
12.3.6.6. Emrok: Sales Forecast, 2023-2035
12.3.6.7. Emrok-O: Sales Forecast, 2023-2035
12.3.6.8. Fetroja®: Sales Forecast, 2023-2035
12.3.6.9. Kimyrsa™: Sales Forecast, 2023-2035
12.3.6.10. Lasvic®: Sales Forecast, 2023-2035
12.3.6.11. Nuzyra®: Sales Forecast, 2023-2035
12.3.6.12. Orbactiv™/Tenkasi: Sales Forecast, 2023-2035
12.3.6.13. Ozanex™: Sales Forecast, 2023-2035
12.3.6.14. Quofenix: Sales Forecast, 2023-2035
12.3.6.15. Recarbrio™: Sales Forecast, 2023-2035
12.3.6.16. Seysara™: Sales Forecast, 2023-2035
12.3.6.17. Solosec®: Sales Forecast, 2023-2035
12.3.6.18. Vabomere™: Sales Forecast, 2023-2035
12.3.6.19. Xenleta™: Sales Forecast, 2023-2035
12.3.6.20. XEPI™: Sales Forecast, 2023-2035
12.3.6.21. Xerava™: Sales Forecast, 2023-2035
12.3.6.22. Xydalba®: Sales Forecast, 2023-2035
12.3.6.23. Youxitai: Sales Forecast, 2023-2035
12.3.6.24. Zemdri™: Sales Forecast, 2023-2035
12.3.6.25. Zerbaxa®: Sales Forecast, 2023-2035
12.3.6.26. Zyvoxam®: Sales Forecast, 2023-2035

12.3.7. Sales Forecast: Clinical-stage Antibiotics
12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2035
12.3.7.2. CONTEPO™: Sales Forecast, 2023-2035
12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2035
12.3.7.4. MBK-01: Sales Forecast, 2023-2035
12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035
12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2035
12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2035
12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035
12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2035
12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035
12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2035
12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035
12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035
12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2035
12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2035
12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2035

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1 Executive Summary: Overall Market Landscape of Approved Antibiotic Generics
Figure 1.2 Executive Summary: Overall Market Landscape of Approved Antibiotic Brands
Figure 1.3 Executive Summary: Overall Market Landscape of Clinical-stage Antibiotics
Figure 1.4 Executive Summary: Partnerships and Collaborations
Figure 1.5 Executive Summary: Clinical Trial Analysis
Figure 1.6 Executive Summary: Key Opinion Leaders
Figure 1.7 Executive Summary: Market Forecast and Opportunity Analysis
Figure 2.1 Classification of Antibiotics
Figure 2.2 History of Antibiotics
Figure 2.3 Mechanism of Action of Antibiotics
Figure 3.1 Approved Antibiotic Generics: Distribution by Year of Approval
Figure 3.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval
Figure 3.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval
Figure 3.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 3.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)
Figure 3.6 Approved Antibiotic Generics: Distribution by Mechanism of Action
Figure 3.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity
Figure 3.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)
Figure 3.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)
Figure 3.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)
Figure 3.11 Approved Antibiotic Generics: Distribution by Nature of Source
Figure 3.12 Approved Antibiotic Generics: Distribution by Type of Therapy
Figure 3.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration
Figure 3.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)
Figure 3.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)
Figure 3.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)
Figure 3.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment
Figure 3.18 Approved Antibiotic Generic Developers: Distribution by Company Size
Figure 3.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters
Figure 3.20 Most Active Players: Distribution by Number of Approved Generics
Figure 4.1 Approved Antibiotic Brands: Distribution by Year of Approval
Figure 4.2 Approved Antibiotic Brands: Distribution by Region(s) of Approval
Figure 4.3 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval
Figure 4.4 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 4.5 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)
Figure 4.6 Approved Antibiotic Brands: Distribution by Mechanism of Action
Figure 4.7 Approved Antibiotic Brands: Distribution by Spectrum of Activity
Figure 4.8 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)
Figure 4.9 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)
Figure 4.10 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)
Figure 4.11 Approved Antibiotic Brands: Distribution by Nature of Source
Figure 4.12 Approved Antibiotic Brands: Distribution by Type of Therapy
Figure 4.13 Approved Antibiotic Brands: Distribution by Route(s) of Administration
Figure 4.14 Approved Antibiotic Brands: Distribution by Dosage Form(s)
Figure 4.15 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)
Figure 4.16 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)
Figure 4.17 Approved Antibiotic Brands: Distribution by Type of Innovation
Figure 4.18 Approved Antibiotic Brand Developers: Distribution by Year of Establishment
Figure 4.19 Approved Antibiotic Brand Developers: Distribution by Company Size
Figure 4.20 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters
Figure 4.21 Most Active Players: Distribution by Number of Approved Brands
Figure 5.1 Clinical-Stage Antibiotics: Distribution by Status of Development
Figure 5.2 Clinical-Stage Antibiotics: Distribution by Stage of Development
Figure 5.3 Clinical-Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 5.4 Clinical-Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)
Figure 5.5 Clinical-Stage Antibiotics: Distribution by Mechanism of Action
Figure 5.6 Clinical-Stage Antibiotics: Distribution by Spectrum of Activity
Figure 5.7 Clinical-Stage Antibiotics: Distribution by Type of Target Bacteria(s)
Figure 5.8 Clinical-Stage Antibiotics: Distribution by Target Bacterial Strain(s)
Figure 5.9 Clinical-Stage Antibiotics: Distribution by Target Disease Indication(s)
Figure 5.10 Clinical-Stage Antibiotics: Distribution by Therapeutic Area(s)
Figure 5.11 Clinical-Stage Antibiotics: Distribution by Nature of Source
Figure 5.12 Clinical-Stage Antibiotics: Distribution by Type of Therapy
Figure 5.13 Clinical-Stage Antibiotics: Distribution by Route(s) of Administration
Figure 5.14 Clinical-Stage Antibiotics: Distribution by Dosage Form(s)
Figure 5.15 Clinical-Stage Antibiotics: Distribution by Dosage Strength
Figure 5.16 Clinical-Stage Antibiotics: Distribution by Dosage Frequency
Figure 5.17 Clinical-Stage Antibiotics: Distribution by Dosing Period
Figure 5.18 Clinical-Stage Antibiotics: Distribution by Type of Patient Population (based on Age)
Figure 5.19 Clinical-Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)
Figure 5.20 Clinical-Stage Antibiotics: Distribution by Special Designation Received
Figure 5.21 Clinical-Stage Antibiotic Developers: Distribution by Year of Establishment
Figure 5.22 Clinical-Stage Antibiotic Developers: Distribution by Company Size
Figure 5.23 Clinical-Stage Antibiotic Developers: Distribution by Location of Headquarters
Figure 5.24 Most Active Players: Analysis by Number of Clinical-stage Antibiotics
Figure 5.25 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
Figure 6.1 Bristol-Myers Squibb: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.2 Bristol-Myers Squibb: Key Strategies
Figure 6.3 Bristol-Myers Squibb: Key Focus Areas
Figure 6.4 Daiichi Sankyo: Annual Revenues, 2017-9M 2022 (JPY Billion)
Figure 6.5 Daiichi Sankyo: Key Strategies
Figure 6.6 Daiichi Sankyo: Key Focus Areas
Figure 6.7 GlaxoSmithKline: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.8 GlaxoSmithKline: Key Strategies
Figure 6.9 GlaxoSmithKline: Key Focus Areas
Figure 6.10 Melinta Therapeutics: Annual Revenues, 2017-6M 2019 (USD Billion)
Figure 6.11 Melinta Therapeutics: Key Strategies
Figure 6.12 Melinta Therapeutics: Key Focus Areas
Figure 6.13 Merck: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.14 Merck: Key Strategies
Figure 6.15 Merck: Key Focus Areas
Figure 6.16 Pfizer: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 6.17 Pfizer: Key Strategies
Figure 6.18 Pfizer: Key Focus Areas
Figure 6.19 Company Profiles: Concluding Remarks
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.6 Partnerships and Collaborations: Distribution by Company Size
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 7.8 Partnerships and Collaborations: Local and International Agreements
Figure 7.9 Partnerships and Collaborations: Distribution by Geography
Figure 7.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 7.11 Most Active Players: Distribution by Number of Partnerships
Figure 7.12 Partnerships and Collaborations: Concluding Remarks
Figure 8.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 8.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)
Figure 8.5 Clinical Trial Analysis: Key Focus Areas
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 8.7 Clinical Trial Analysis: Distribution by Geography
Figure 8.8 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 8.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 8.10 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography
Figure 8.11 Most Active Industry Players: Analysis by Number of Trials
Figure 8.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 9.1 KOL Analysis: Distribution by Type of KOL
Figure 9.2 KOL Analysis: Distribution by Qualification
Figure 9.3 KOL Analysis: Distribution by Type of Organization
Figure 9.4 KOL Analysis: Distribution by Affiliated Organization
Figure 9.5 KOL Analysis: Distribution by Geographical Location of KOLs
Figure 9.6 KOL Analysis: Distribution by Target Disease Indication(s)
Figure 9.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 9.8 Most Prominent KOLs: Peer Group 1 (Other Types of Investigators)
Figure 9.9 Most Prominent KOLs: Distribution by RA score
Figure 9.10 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Figure 9.11 KOL Analysis: Concluding Remarks
Figure 10.1. Drug-Pricing Analysis: Distribution by Geography
Figure 10.2. Key Antibiotic Developers: Outsourcing Trends
Figure 11.1. Dovprela (TB Alliance): Success Protocol Analysis
Figure 11.2. Fetroja (Shionogi): Success Protocol Analysis
Figure 11.3 Kimyrsa (Melinta Therapeutics): Success Protocol Analysis
Figure 11.4 Recarbrio (Merck): Success Protocol Analysis
Figure 11.5 Quofenix (Menarini): Success Protocol Analysis
Figure 11.6 Xenleta (Nabriva Therapeutics): Success Protocol Analysis
Figure 11.7 Success Protocol Analysis: Concluding Remarks
Figure 12.1 Global Antibiotics Market, 2023-2035 (USD Billion)
Figure 12.2 Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035 (USD Billion)
Figure 12.3 Antibiotics Market for Aminoglycosides, 2023-2035 (USD Billion)
Figure 12.4 Antibiotics Market for Cephalosporins, 2023-2035 (USD Billion)
Figure 12.5 Antibiotics Market for Fluoroquinolones, 2023-2035 (USD Billion)
Figure 12.6 Antibiotics Market for Macrolides, 2023-2035 (USD Billion)
Figure 12.7 Antibiotics Market for Oxazolidinones, 2023-2035 (USD Billion)
Figure 12.8 Antibiotics Market for Penicillins, 2023-2035 (USD Billion)
Figure 12.9 Antibiotics Market for Sulphonamides, 2023-2035 (USD Billion)
Figure 12.10 Antibiotics Market for Tetracyclines, 2023-2035 (USD Billion)
Figure 12.11 Antibiotics Market for Other Classes, 2023-2035 (USD Billion)
Figure 12.12 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)
Figure 12.13 Antibiotics Market for Bacterial Infections, 2023-2035 (USD Billion)
Figure 12.14 Antibiotics Market for Dermatological Infections, 2023-2035 (USD Billion)
Figure 12.15 Antibiotics Market for Gastrointestinal Infections, 2023-2035 (USD Billion)
Figure 12.16 Antibiotics Market for Nephrological Infections, 2023-2035 (USD Billion)
Figure 12.17 Antibiotics Market for Pulmonary Infections, 2023-2035 (USD Billion)
Figure 12.18 Antibiotics Market for Reproductive Tract Infections, 2023-2035 (USD Billion)
Figure 12.19 Antibiotics Market for Respiratory Tract Infections, 2023-2035 (USD Billion)
Figure 12.20 Antibiotics Market for Sexually Transmitted Diseases, 2023-2035 (USD Billion)
Figure 12.21 Antibiotics Market for Urinary Tract Infections, 2023-2035 (USD Billion)
Figure 12.22 Antibiotics Market for Other Bacterial Infections, 2023-2035 (USD Billion)
Figure 12.23 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)
Figure 12.24 Antibiotics Market for Monotherapies, 2023-2035 (USD Billion)
Figure 12.25 Antibiotics Market for Combination Therapies, 2023-2035 (USD Billion)
Figure 12.26 Antibiotics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
Figure 12.27 Antibiotics Market for Intravenous Therapies, 2023-2035 (USD Billion)
Figure 12.28 Antibiotics Market for Oral Therapies, 2023-2035 (USD Billion)
Figure 12.29 Antibiotics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Figure 12.30 Antibiotics Market in North America, 2023-2035 (USD Billion)
Figure 12.31 Antibiotics Market in Europe, 2023-2035 (USD Billion)
Figure 12.32 Antibiotics Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure.13.33 Antibiotics Market in Rest of the World, 2023-2035 (USD Billion)
Figure.13.34 Aemcolo®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.35 Arikayce®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.36 Baxdela™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.37 Dalacin C: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.38 Dovprela®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.39 Emrok: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.40 Emrok-O: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.41 Fetroja®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.42 Kimyrsa™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.43 Lasvic®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.44 Nuzyra®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.45 Orbactiv™/Tenkasi: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.46 Ozanex™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.47 Quofenix: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.48 Recarbrio™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.49 Seysara™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.50 Solosec®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.51 Vabomere™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.52 Xenleta™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.53 XEPI™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.54 Xerava™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.55 Xydalba®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.56 Youxitai: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.57 Zemdri™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.58 Zerbaxa®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.59 Zyvoxam®: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.60 Cefepime-Taniborbactam: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.61 CONTEPO™: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.62 Gepotidacin (GSK2140944): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.63 MBK-01: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.64 MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.65 Nafithromycin (WCK 4873): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.66 RHB-104 (rifabutin, rifabutin, and clofazimin): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.67. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.68 Ridinilazole (SMT 19969): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.69 Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.70 Tebipenem HBr: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.71 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.72 WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.73 XNW4107 (Funobactam): Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.74 Zabofloxacin: Sales Forecast, 2023-2035 (USD Billion)
Figure. 13.75 Zoliflodacin (ETX0914): Sales Forecast, 2023-2035 (USD Billion)

List Of Tables

Table 3.1 Approved Antibiotic Generics: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action, and Spectrum of Activity
Table 3.2 Approved Antibiotic Generics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy
Table 3.3 Approved Antibiotic Generics: Information on Route(s) of Administration. Dosage Form(s), and Type of Patient Population (based on Age and Gender)
Table 3.4 Approved Antibiotic Generics: List of Developers
Table 4.1 Approved Antibiotic Brands: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity
Table 4.2 Approved Antibiotic Brands: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy
Table 4.3 Approved Antibiotic Brands: Information on Route(s) of Administration, Dosage Form(s), Type of Patient Population (based on Age and Gender) and Type of Innovation
Table 4.4 Approved Antibiotic Brands: List of Developers
Table 5.1 Clinical-stage Antibiotics: Information on Status of Development, Stage of Development, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity
Table 5.2 Clinical-stage Antibiotics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Therapeutic Area, Nature of Source and Type of Therapy
Table 5.3 Clinical-stage Antibiotics: Information on Route(s) of Administration,Dosage Form(s), Dosage Strength, Dosage Frequency and Dosing Period
Table 5.4 Clinical-stage Antibiotics: Information on Type of Patient Population (based on Age and Gender)
Table 5.5 Clinical-stage Antibiotics: List of Developers
Table 6.1 Bristol-Myers Squibb: Product Portfolio
Table 6.2 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.3 Daiichi Sankyo: Product Portfolio
Table 6.4 Daiichi Sankyo: Recent Developments and Future Outlook
Table 6.5 GlaxoSmithKline: Product Portfolio
Table 6.6 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.7 Melinta Therapeutics: Product Portfolio
Table 6.8 Melinta Therapeutics: Recent Developments and Future Outlook
Table 6.9 Merck: Product Portfolio
Table 6.10 Merck: Recent Developments and Future Outlook
Table 6.11 Pfizer: Product Portfolio
Table 6.12 Pfizer: Recent Developments and Future Outlook
Table 7.1 Antibiotics: List of Partnerships and Collaborations
Table 8.1. Antibiotics: List of Clinical Trials
Table 9.1. Antibiotics: List of Key Opinion Leaders (KOLs)
Table 10.1. Antibiotics Industry: List of Recent Expansions
Table 11.1 Sales Forecast: List of Approved Antibiotics
Table 12.1 Sales Forecast: List of Clinical-stage Antibiotics
Table 13.1 Approved Antibiotic Generics: Distribution by Year of Approval
Table 13.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval
Table 13.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval
Table 13.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.6 Approved Antibiotic Generics: Distribution by Mechanism of Action
Table 13.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity
Table 13.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)
Table 13.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)
Table 13.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)
Table 13.11 Approved Antibiotic Generics: Distribution by Nature of Source
Table 13.12 Approved Antibiotic Generics: Distribution by Type of Therapy
Table 13.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration
Table 13.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)
Table 13.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)
Table 13.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)
Table 13.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment
Table 13.18 Approved Antibiotic Generic Developers: Distribution by Company Size
Table 13.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters
Table 13.20 Most Active Players: Distribution by Number of Approved Generics
Table 13.21 Approved Antibiotic Brands: Distribution by Year of Approval
Table 13.22 Approved Antibiotic Brands: Distribution by Region(s) of Approval
Table 13.23 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval
Table 13.24 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.25 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.26 Approved Antibiotic Brands: Distribution by Mechanism of Action
Table 13.27 Approved Antibiotic Brands: Distribution by Spectrum of Activity
Table 13.28 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)
Table 13.29 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)
Table 13.30 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)
Table 13.31 Approved Antibiotic Brands: Distribution by Nature of Source
Table 13.32 Approved Antibiotic Brands: Distribution by Type of Therapy
Table 13.33 Approved Antibiotic Brands: Distribution by Route(s) of Administration
Table 13.34 Approved Antibiotic Brands: Distribution by Dosage Form(s)
Table 13.35 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)
Table 13.36 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)
Table 13.37 Approved Antibiotic Brands: Distribution by Type of Innovation
Table 13.38 Approved Antibiotic Brand Developers: Distribution by Year of Establishment
Table 13.39 Approved Antibiotic Brand Developers: Distribution by Company Size
Table 13.40 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters
Table 13.41 Most Active Players: Distribution by Number of Approved Brands
Table 13.42 Clinical-Stage Antibiotics: Distribution by Status of Development
Table 13.43 Clinical-Stage Antibiotics: Distribution by Stage of Development
Table 13.44 Clinical-Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.45 Clinical-Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.46 Clinical-Stage Antibiotics: Distribution by Mechanism of Action
Table 13.47 Clinical-Stage Antibiotics: Distribution by Spectrum of Activity
Table 13.48 Clinical-Stage Antibiotics: Distribution by Type of Target Bacteria(s)
Table 13.49 Clinical-Stage Antibiotics: Distribution by Target Bacterial Strain(s)
Table 13.50 Clinical-Stage Antibiotics: Distribution by Target Disease Indication(s)
Table 13.51 Clinical-Stage Antibiotics: Distribution by Therapeutic Area(s)
Table 13.52 Clinical-Stage Antibiotics: Distribution by Nature of Source
Table 13.53 Clinical-Stage Antibiotics: Distribution by Type of Therapy
Table 13.54 Clinical-Stage Antibiotics: Distribution by Route(s) of Administration
Table 13.55 Clinical-Stage Antibiotics: Distribution by Dosage Form(s)
Table 13.56 Clinical-Stage Antibiotics: Distribution by Dosage Strength
Table 13.57 Clinical-Stage Antibiotics: Distribution by Dosage Frequency
Table 13.58 Clinical-Stage Antibiotics: Distribution by Dosing Period
Table 13.59 Clinical-Stage Antibiotics: Distribution by Type of Patient Population (based on Age)
Table 13.60 Clinical-Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)
Table 13.61 Clinical-Stage Antibiotics: Distribution by Special Designation Received
Table 13.62 Clinical-Stage Antibiotic Developers: Distribution by Year of Establishment
Table 13.63 Clinical-Stage Antibiotic Developers: Distribution by Company Size
Table 13.64 Clinical-Stage Antibiotic Developers: Distribution by Location of Headquarters
Table 13.65 Most Active Players: Analysis by Number of Clinical-stage Antibiotics
Table 13.66 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
Table 13.67 Partnerships and Collaborations: Distribution by Year of Partnership
Table 13.68 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.69 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.70 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.72 Partnerships and Collaborations: Distribution by Company Size
Table 13.73 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 13.74 Partnerships and Collaborations: Local and International Agreements
Table 13.75 Partnerships and Collaborations: Distribution by Geography
Table 13.76 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 13.77 Most Active Players: Distribution by Number of Partnerships
Table 13.78 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 13.79 Clinical Trial Analysis: Distribution by Trial Status
Table 13.80 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.81 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)
Table 13.82 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.83 Clinical Trial Analysis: Distribution by Geography
Table 13.84 Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 13.85 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 13.86 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography
Table 13.87 Most Active Industry Players: Analysis by Number of Trials
Table 13.88 Most Active Non-Industry Players: Analysis by Number of Trials
Table 13.89 KOL Analysis: Distribution by Type of KOL
Table 13.90 KOL Analysis: Distribution by Qualification
Table 13.91 KOL Analysis: Distribution by Type of Organization
Table 13.92 KOL Analysis: Distribution by Affiliated Organization
Table 13.93 KOL Analysis: Distribution by Geographical Location of KOLs
Table 13.94 KOL Analysis: Distribution by Target Disease Indication(s)
Table 13.95 Global Antibiotics Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.96 Antibiotics Market: Distribution by Type of Antibiotic (based on Drug Class), 2023 and 2035 (USD Billion)
Table 13.97 Antibiotics Market for Aminoglycosides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.98 Antibiotics Market for Cephalosporins, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.99 Antibiotics Market for Fluoroquinolones, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.100 Antibiotics Market for Macrolides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.101 Antibiotics Market for Oxazolidinones, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.102 Antibiotics Market for Penicillins, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.103 Antibiotics Market for Sulphonamides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.104 Antibiotics Market for Tetracyclines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.105 Antibiotics Market for Other Classes, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.106 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)
Table 13.107 Antibiotics Market for Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.108 Antibiotics Market for Dermatological Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.109 Antibiotics Market for Gastrointestinal Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.110 Antibiotics Market for Nephrological Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.111 Antibiotics Market for Pulmonary Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.112 Antibiotics Market for Reproductive Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.113 Antibiotics Market for Respiratory Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.114 Antibiotics Market for Sexually Transmitted Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.115 Antibiotics Market for Urinary Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.116 Antibiotics Market for Other Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.117 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)
Table 13.118 Antibiotics Market for Monotherapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.119 Antibiotics Market for Combination Therapies, 2023-2035 (USD Billion)
Table 13.120 Antibiotics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
Table 13.121 Antibiotics Market for Intravenous Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.122 Antibiotics Market for Oral Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.123 Antibiotics Market: Distribution by Geography, 2023 and 2035
Table 13.124 Antibiotics Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.125 Antibiotics Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.126 Antibiotics Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.127 Antibiotics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.128 Aemcolo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.129 Arikayce®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.130 Baxdela™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion))
Table 13.131 Dalacin C: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.132 Dovprela®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.133 Emrok: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.134 Emrok-O: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.135 Fetroja®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.136 Kimyrsa™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.137 Lasvic®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.138 Nuzyra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.139 Orbactiv™/Tenkasi: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.140 Ozanex™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.141 Quofenix: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.142 Recarbrio™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.143 Seysara™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.144 Solosec®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.145 Vabomere™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.146 Xenleta™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.147 XEPI™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.148 Xerava™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.149 Xydalba®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.150 Youxitai: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.151 Zemdri™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.152 Zerbaxa®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.153 Zyvoxam®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.154 Cefepime-Taniborbactam: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.155 CONTEPO™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.156 Gepotidacin (GSK2140944): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.157 MBK-01: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.158 MRX-4 (Contezolid Acefosamil): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.159 Nafithromycin (WCK 4873): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.160 RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.161 RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.162 Ridinilazole (SMT 19969): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.163 Sulopenem- etzadroxil- probenecid: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.164 Tebipenem HBr: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.165 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, , Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.166 WCK 5222 (cefepime + zidebactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.167 XNW4107 (Funobactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.168 Zabofloxacin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 13.169 Zoliflodacin (ETX0914): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. Abbott
  2. ABAC Therapeutics
  3. AbbVie
  4. Aceragen
  5. Acurx Pharmaceuticals
  6. Affinivax (a subsidiary of GlaxoSmithKline) 
  7. AGILeBiotics 
  8. Alcon
  9. Alfa Wassermann
  10. Allecra Therapeutics
  11. Angelini Pharma
  12. Antimicrobials Working Group (AWG)
  13. Aptuit
  14. Ares Genetics (acquired by OpGen)
  15. Arrevus (a subsidiary of Aceragen)
  16. Astellas Pharma (formerly known as Fujisawa Pharmaceutical)
  17. B. Braun
  18. Basilea Pharmaceutica
  19. Bayer
  20. Bill & Melinda Gates Foundation
  21. Bill & Melinda Gates Medical Research Institute
  22. BIOASTER
  23. Biocidium Biopharmaceuticals
  24. bioMérieux
  25. BioVersys 
  26. Blacksmith Medicines
  27. Boulos and Cooper Pharmaceuticals
  28. Brii Biosciences
  29. Bristol-Myers Squibb
  30. Bugworks Research
  31. Calibr
  32. Cardiome Pharma
  33. Catalent
  34. Chia Tai Tianqing Pharmaceutical
  35. Cipla
  36. Colgate-Palmolive
  37. Commonwealth Scientific and Industrial Research Organization
  38. ContraFect
  39. Cosmo Pharmaceuticals
  40. Cosmo Technologies
  41. Crestone
  42. CrystalGenomics
  43. Cubist Pharmaceuticals
  44. Curetis
  45. Daiichi Sankyo
  46. Damascus Hospital
  47. Debiopharm
  48. Defense Threat Reduction Agency (DTRA)
  49. DEINOVE
  50. Department of Health and Human Services
  51. Discuva (a subsidiary of Summit Therapeutics) 
  52. Dongwha Pharmaceutical
  53. Entasis Therapeutics
  54. Er-Kim Pharmaceuticals
  55. Eurofarma
  56. Everest Medicines
  57. EVERSANA
  58. Evotec
  59. Exeltis
  60. Fedora Pharmaceuticals
  61. Ferrer Internacional
  62. Forest Laboratories
  63. Forge Therapeutics (a subsidiary of Blacksmith Medicines)
  64. Fosun Pharma
  65. Foundation for Neglected Disease Research (FNDR)
  66. French National Agency for the Safety of Medicines and Health Products (ANSM)
  67. Fresenius Kabi
  68. Fujifilm
  69. Genentech
  70. Gilead Sciences
  71. GlaxoSmithKline
  72. Global Antibiotic Research and Development Partnership (GARDP)
  73. HanaVax
  74. Hartford Healthcare
  75. Helperby Therapeutics
  76. Helsinki University Hospital
  77. Hikma Pharmaceuticals
  78. Hoffmann-La Roche
  79. Hsiri Therapeutics
  80. Huazhong University of Science and Technology
  81. HUTCHMED
  82. Idera Pharmaceuticals
  83. Infex Therapeutics
  84. Innoviva
  85. Insmed
  86. Institut Pasteur de Lille
  87. InveniAI
  88. Iterum Therapeutics
  89. Janssen Pharmaceutical
  90. JEIL Pharmaceutical
  91. Juvabis
  92. KBP Biosciences
  93. Kyorin Pharmaceutical
  94. Kyoto Pharmaceutical
  95. Kyowa Hakko Bio
  96. La Jolla Pharmaceutical Company
  97. LANCET Pharmaceuticals
  98. LegoChem Biosciences
  99. LifeArc
  100. Liverpool School of Tropical Medicine
  101. Lupin
  102. MacKay Memorial Hospital
  103. Macleods Pharmaceuticals
  104. Madam Therapeutics
  105. Mahidol University
  106. Maruho 
  107. Medical College of Wisconsin
  108. Medicines for Malaria Venture (MMV)
  109. Medimetriks Pharmaceuticals
  110. Medpace
  111. Meiji Seika Pharma
  112. Melinta Therapeutics
  113. Merck
  114. MGB Biopharma
  115. MicuRx Pharmaceuticals
  116. Mikrobiomik
  117. Mitsubishi Tanabe Pharma
  118. Monash University
  119. Morphochem (a subsidiary of DEINOVE)
  120. Mylan
  121. Nabriva Therapeutics
  122. NAICONS
  123. Nanjing Neiwa Faith
  124. National Institute of Allergy and Infectious Diseases
  125. Nippon Shinyaku
  126. Novartis
  127. NovoSci Healthcare
  128. Optimer Pharmaceuticals
  129. Otsuka Pharmaceutical
  130. Paratek Pharmaceuticals
  131. Pasteur Institute
  132. Peking University Shenzhen Hospital
  133. Peptris Technologies
  134. Perrigo
  135. Pfizer
  136. Pharmacia & Upjohn
  137. Ping An-Shionogi
  138. PLIVA Hrvatska
  139. Qpex Biopharma
  140. Rambam Health Care Campus
  141. RedHill Biopharma
  142. Redx Pharma
  143. Research Institute of the McGill University Health Centre
  144. RS Oncology
  145. Samenwerkingsverband Noord-Nederland (SNN)
  146. Sandoz
  147. Sanofi
  148. Schrödinger
  149. Selmod
  150. Senju Pharmaceutical
  151. Sequella
  152. Shandong University
  153. Shanghai Jiao Tong University School of Medicine
  154. Shanghai Zhongshan Hospital
  155. Shenyang Hongqi Pharmaceutical
  156. Shenzhen China Resources Gosun Pharmaceuticals
  157. Shionogi
  158. SIGA Technologies
  159. Sinovent
  160. Spero Therapeutics
  161. Spexis 
  162. Sumitomo Pharma
  163. Summit Therapeutics
  164. TaBriX
  165. Taisho Pharmaceutical
  166. Takeda Pharmaceuticals
  167. Tanta University
  168. TB Alliance
  169. Telethon Kids Institute
  170. Teligent
  171. TenNor Therapeutics
  172. Tetraphase Pharmaceuticals (a subsidiary of La Jolla Pharmaceutical Company)
  173. The University of Geneva
  174. The University of Manchester
  175. Theravance Biopharma
  176. Theriva Biologics
  177. University Medical Center Groningen
  178. University of California
  179. University of Electronic Science and Technology of China
  180. University of Lille
  181. University of Southern California
  182. University of Wisconsin
  183. Valeant Pharmaceuticals
  184. Venatorx Pharmaceuticals
  185. Vizient
  186. WEP Clinical
  187. Wockhardt 
  188. WuXi AppTec
  189. Wyeth Pharmaceuticals
  190. Zai Lab
  191. ZebiAI

Source 1: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
Source 2: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html

Segmentation

Segmentation

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com